TW202309025A - Parp1抑制劑及其用途 - Google Patents

Parp1抑制劑及其用途 Download PDF

Info

Publication number
TW202309025A
TW202309025A TW111114905A TW111114905A TW202309025A TW 202309025 A TW202309025 A TW 202309025A TW 111114905 A TW111114905 A TW 111114905A TW 111114905 A TW111114905 A TW 111114905A TW 202309025 A TW202309025 A TW 202309025A
Authority
TW
Taiwan
Prior art keywords
alkyl
cycloalkyl
pharmaceutically acceptable
haloalkyl
solvate
Prior art date
Application number
TW111114905A
Other languages
English (en)
Chinese (zh)
Inventor
琳妮 特洛斯
慶 董
斯蒂芬 W 卡爾多
羅伯特 L 霍夫曼
波里諾 金久 法
約瑟夫 羅伯特 披切曼
Original Assignee
美商辛瑟拉股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商辛瑟拉股份有限公司 filed Critical 美商辛瑟拉股份有限公司
Publication of TW202309025A publication Critical patent/TW202309025A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW111114905A 2021-04-19 2022-04-19 Parp1抑制劑及其用途 TW202309025A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163176610P 2021-04-19 2021-04-19
US63/176,610 2021-04-19
US202163183563P 2021-05-03 2021-05-03
US63/183,563 2021-05-03
US202163254832P 2021-10-12 2021-10-12
US63/254,832 2021-10-12

Publications (1)

Publication Number Publication Date
TW202309025A true TW202309025A (zh) 2023-03-01

Family

ID=83723349

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111114905A TW202309025A (zh) 2021-04-19 2022-04-19 Parp1抑制劑及其用途

Country Status (8)

Country Link
US (2) US11591331B2 (cg-RX-API-DMAC7.html)
EP (1) EP4326720A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024514223A (cg-RX-API-DMAC7.html)
KR (1) KR20230172550A (cg-RX-API-DMAC7.html)
AU (1) AU2022260495B2 (cg-RX-API-DMAC7.html)
CA (1) CA3216373A1 (cg-RX-API-DMAC7.html)
TW (1) TW202309025A (cg-RX-API-DMAC7.html)
WO (1) WO2022225934A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI926045B (zh) * 2021-05-24 2026-05-21 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類化合物、其製備方法及其在醫藥上的應用

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
WO2022222921A1 (zh) * 2021-04-22 2022-10-27 微境生物医药科技(上海)有限公司 含哌嗪结构的parp抑制剂、其制备方法及医药用途
CN116601148A (zh) * 2021-04-23 2023-08-15 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
AU2022334408A1 (en) * 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046158A1 (zh) * 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
WO2023051812A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 含氮杂环衍生物parp抑制剂及其用途
TWI876212B (zh) * 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
CA3238572A1 (en) * 2021-11-19 2023-05-25 Jing Zhang Selective parp1 inhibitor and application thereof
CN118382624A (zh) * 2021-12-17 2024-07-23 凯复(苏州)生物医药有限公司 Parp抑制剂、包含其的药物组合物及其用途
WO2023133413A1 (en) * 2022-01-07 2023-07-13 Slap Pharmaceuticals Llc Multicyclic compounds
US20250221987A1 (en) * 2022-01-13 2025-07-10 Acerand Therapeutics (Hong Kong) Limited Piperazino ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof
CN118434725B (zh) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
CA3246093A1 (en) * 2022-01-27 2023-08-03 Xinthera, Inc. PARP1 INHIBITORS AND THEIR USES
AU2023212785A1 (en) * 2022-01-28 2024-08-15 Xinthera, Inc. Parp1 inhibitors and uses thereof
AU2023229992A1 (en) * 2022-03-11 2024-10-10 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and the use thereof
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
EP4514795A4 (en) * 2022-04-28 2025-12-31 Ningbo Newbay Tech Development Co Ltd COMPOUNDS USED AS PARP1 INHIBITORS
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
US20250346573A1 (en) * 2022-06-02 2025-11-13 Chengdu Easton Biopharmaceuticals Co., Ltd. Azaquinolinone derivative, preparation method therefor and use thereof
CN115919859B (zh) * 2022-07-14 2024-01-05 四川海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
CN119677736A (zh) * 2022-08-24 2025-03-21 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
CN118139862A (zh) * 2022-09-30 2024-06-04 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
US20240174669A1 (en) 2022-10-06 2024-05-30 Xinthera, Inc. Crystalline forms of a parp1 inhibitor
WO2024083218A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
WO2024083201A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
CN120035592A (zh) * 2022-10-20 2025-05-23 成都赜灵生物医药科技有限公司 并杂环类氘代化合物及其用途
AU2023378452A1 (en) * 2022-11-10 2025-06-19 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof
WO2024099386A1 (zh) * 2022-11-10 2024-05-16 正大天晴药业集团股份有限公司 稠合双环化合物
AU2023412594A1 (en) * 2022-12-23 2025-07-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Parp1 inhibitors
WO2024158878A1 (en) * 2023-01-25 2024-08-02 Enliven Inc. Fused tetracyclic selective parp1 inhibitors
WO2024178125A1 (en) * 2023-02-21 2024-08-29 1Cbio, Inc. Heterocyclic compounds and methods of use thereof
TW202502341A (zh) * 2023-03-13 2025-01-16 大陸商江蘇豪森藥業集團有限公司 哌啶烯類化合物在製備治療癌症的藥物中的應用
EP4688769A1 (en) * 2023-03-24 2026-02-11 Xinthera, Inc. Crystalline forms of an azetidine parp1 inhibitor
TW202506680A (zh) * 2023-04-28 2025-02-16 美商思諾維新醫藥公司 作為parp1抑制劑之雜環化合物
WO2024240108A1 (zh) * 2023-05-19 2024-11-28 上海海和药物研究开发股份有限公司 一种芳基脲类parp1抑制剂、其制备方法及用途
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
CN121464135A (zh) * 2023-07-07 2026-02-03 优领医药科技(香港)有限公司 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用
CN119462669A (zh) * 2023-08-11 2025-02-18 上海海和药物研究开发股份有限公司 稠合三环类化合物、其药物组合物和用途
WO2025092973A1 (zh) * 2023-11-03 2025-05-08 成都赜灵生物医药科技有限公司 Parp1靶向化合物及其用途
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用
WO2025261449A1 (zh) * 2024-06-19 2025-12-26 浙江扬厉医药技术有限公司 一种parp1抑制剂吡啶酰胺类化合物、中间体及其制备方法
WO2025261448A1 (zh) * 2024-06-19 2025-12-26 浙江扬厉医药技术有限公司 一类吡啶酰胺化合物的盐型、晶型及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
EP2389379A1 (en) * 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
US8541417B2 (en) * 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
EA028506B1 (ru) 2012-10-26 2017-11-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные 4-карбоксамидо-изоиндолинона в качестве селективных ингибиторов parp-1, способ их получения и применение
PT3312177T (pt) 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
IL301921A (en) * 2020-10-09 2023-06-01 Daiichi Sankyo Co Ltd Combining an antibody-drug conjugate and a selective 1PARP inhibitor
TW202309025A (zh) 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
WO2022222921A1 (zh) 2021-04-22 2022-10-27 微境生物医药科技(上海)有限公司 含哌嗪结构的parp抑制剂、其制备方法及医药用途
CN116601148A (zh) * 2021-04-23 2023-08-15 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
CN116710433B (zh) 2021-04-23 2026-05-05 康百达(四川)生物医药科技有限公司 一种选择性parp1抑制剂及其应用
CN116867783B (zh) 2021-04-23 2026-08-07 康百达(四川)生物医药科技有限公司 吡啶衍生物及其在医药上的应用
WO2022228387A1 (en) * 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023051807A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 双环衍生物parp抑制剂及其用途
CN118382624A (zh) * 2021-12-17 2024-07-23 凯复(苏州)生物医药有限公司 Parp抑制剂、包含其的药物组合物及其用途
US20250221987A1 (en) * 2022-01-13 2025-07-10 Acerand Therapeutics (Hong Kong) Limited Piperazino ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof
CN118434725B (zh) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN115232129B (zh) 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI926045B (zh) * 2021-05-24 2026-05-21 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類化合物、其製備方法及其在醫藥上的應用

Also Published As

Publication number Publication date
EP4326720A4 (en) 2025-03-19
KR20230172550A (ko) 2023-12-22
JP2024514223A (ja) 2024-03-28
US11591331B2 (en) 2023-02-28
US20230128041A1 (en) 2023-04-27
CA3216373A1 (en) 2022-10-27
US20220348574A1 (en) 2022-11-03
WO2022225934A1 (en) 2022-10-27
AU2022260495B2 (en) 2026-07-30
AU2022260495A1 (en) 2023-10-05
EP4326720A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
US11591331B2 (en) PARP1 inhibitors and uses thereof
TWI876212B (zh) 吖丁啶及吡咯啶parp1抑制劑及其用途
CN104520290B (zh) 酰氨基螺环酰胺和磺酰胺衍生物
JP2022518860A (ja) 免疫調節剤、組成物およびその使用方法
CN117177972A (zh) Parp1抑制剂及其用途
JP7607841B1 (ja) Parp1阻害薬及びその使用
CN115433163A (zh) Nlrp3炎症小体抑制剂及其应用
JP2025503798A (ja) ピペラジン縮合環系含有誘導体、その薬学的に許容される塩及びその製造方法と使用
KR20170117479A (ko) 치환된 모노- 및 폴리아자나프탈렌 유도체 및 이의 용도
CN107072985A (zh) 治疗性抑制化合物
TW202400596A (zh) 三環parp1抑制劑及其用途
CA2735779A1 (en) Bicyclic kinase inhibitors
CN118119629A (zh) 含氮杂环类化合物及其医药用途
WO2025045145A1 (zh) 一种抑制wrn解旋酶的双杂环衍生物、含其的药物组合物及其应用
CN120590414A (zh) 一类含氮杂环类化合物、制备方法和用途
CN104530046B (zh) 二氮杂螺类化合物及其在药物中的应用
JP2021116240A (ja) (ヘテロ)アリールイミダゾロン化合物
HK40105522A (en) Parp1 inhibitors and uses thereof
CN118359631A (zh) 多环类PI3Kα抑制剂
TW202610642A (zh) Pde3a/slfn12干擾物、製備及其用途
CN119371425A (zh) 含氮杂环类化合物及其制备方法和医药用途
CN117843567A (zh) 双氮杂芳环取代的苯衍生物及其组合物和用途
EA049024B1 (ru) Ингибиторы parp1 на основе азетидина и пирролидина и их применение
HK1241705A1 (zh) 治疗性抑制化合物